Barclays lowered the firm’s price target on Bruker (BRKR) to $60 from $65 and keeps an Overweight rating on the shares. The firm sees elevated skepticism on the implied OMx ramp throughout the year given the Q1 guidance coming in below expectations.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.